Alzheimer’s could be a ‘very big category’ for Eli Lilly: former FDA commissioner

June 10, 2024 05:17 PM PDT | By Invezz
 Alzheimer’s could be a ‘very big category’ for Eli Lilly: former FDA commissioner
Image source: Invezz

Alzheimer’s could eventually be a “very big category” for Eli Lilly & Co (NYSE: LLY), says Dr Scott Gottlieb. He’s the former commission of the U.S. Food & Drug Administration.

FDA advisors vote in favour of Lilly’s donanemab

Lilly received backing for its Alzheimer’s drug from a panel of advisors to the FDA on Monday.

It’s an “important development for patients” because donanemab is more efficacious and required just one dose per month versus two for a similar drug from Biogen, Dr Gottlieb added in an interview with CNBC today.

Still, Biogen has called its Alzheimer’s drug that targets tau proteins the “crown jewel of the organisation”. J&J also expects its similar under development drug to eventually bring in “$5.0 billion a year”.

That’s why Dr Gottlieb is positive on what the Alzheimer’s treatment may mean for Eli Lilly & Co moving forward.

Eli Lilly is committed to Alzheimer’s treatment

Dr Scott Gottlieb was all praise for Eli Lilly’s donanemab on Monday because it’s a treatment for the “underlying biology of [Alzheimer’s] disease” and not just its symptoms. That helps “prevent progression”, he noted.

Note that the healthcare behemoth is working on a second-gen Alzheimer’s drug as well. It’s scheduled to report data for that subcutaneous treatment in 2025.

The former FDA commissioner expects subcutaneous treatments to be used much more broadly as they will not need to be administered under strict medical supervision.

Wall Street currently has a consensus “buy” rating on Eli Lilly stock that pays a dividend yield of 0.60% at writing. Watch here: https://www.youtube.com/embed/89b6p4Rj5Ds?feature=oembed

What’s next for $LLY in Alzheimer’s space?

Dr Gottlieb talked of the need to win FDA approvals for Alzheimer’s drugs to be administered in the early-stage of the disease on Monday.

He touched on potential for donanemab (or its follow-on formulations) to be an even bigger benefit for $LLY if it makes its way to Medicare coverage as well.

Eli Lilly saw its revenue come in shy of Street estimates in its latest reported quarter. Still, it raised its guidance for the full year to well above expectations in April (read more). David A. Ricks – chief executive of the New York listed giant said at the time:

As we continue to make pipeline investments that position us for future growth, we’re rapidly expanding manufacturing capacity to make our incretin medicines available to more patients.

Eli Lilly stock is currently up roughly 45% versus the start of 2024.

The post Alzheimer’s could be a ‘very big category’ for Eli Lilly: former FDA commissioner appeared first on Invezz


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next